bioAffinity Technologies reports 111% jump in october lung test volume

bioAffinity Technologies Inc. (NASDAQ: BIAF) reported that its CyPath Lung diagnostic test processed 111% more tests in October 2025 compared to the company's year-to-date monthly average, according to a press release statement.

The San Antonio-based biotechnology company said test volume has increased consistently each month in 2025, with October continuing an upward trend. Third-quarter sales volume increased 95% over the prior quarter, the company reported.

Medical practices placing multiple CyPath Lung orders increased 106% in the third quarter compared to the previous quarter and rose 67% in October versus the 2025 year-to-date monthly average, according to the company.

"The increase in CyPath Lung test volume demonstrates that physicians are increasingly recognizing the clinical value of CyPath Lung in detecting lung cancer at its earliest and most treatable stages," said Maria Zannes, president and chief executive officer.

CyPath Lung uses flow cytometry and artificial intelligence to analyze patient sputum samples for cancer cell populations. The noninvasive test is marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services, a bioAffinity Technologies subsidiary.

Clinical study results showed CyPath Lung achieved 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in high-risk patients with lung nodules smaller than 20 millimeters, the company stated.

bioAffinity Technologies focuses on noninvasive diagnostics for lung cancer and other lung diseases. The company's stock also trades under the warrant symbol BIAFW on NASDAQ.

You May Also Be Interested In